Literature DB >> 15047835

Fatty acid synthase expression is induced by the Epstein-Barr virus immediate-early protein BRLF1 and is required for lytic viral gene expression.

Yuling Li1, Jennifer Webster-Cyriaque, Christine C Tomlinson, Marielle Yohe, Shannon Kenney.   

Abstract

The Epstein-Barr virus (EBV) immediate-early (IE) protein BRLF1 (R) is a transcription factor that induces the lytic form of EBV infection. R activates certain early viral promoters through a direct binding mechanism but induces transcription of the other EBV IE gene, BZLF1 (Z), indirectly through cellular factors binding to a CRE motif in the Z promoter (Zp). Here we demonstrate that R activates expression of the fatty acid synthase (FAS) cellular gene through a p38 stress mitogen-activated protein kinase-dependent mechanism. B-cell receptor engagement of Akata cells also increases FAS expression. The FAS gene product is required for de novo synthesis of the palmitate fatty acid, and high-level FAS expression is normally limited to liver, brain, lung, and adipose tissue. We show that human epithelial tongue cells lytically infected with EBV (from oral hairy leukoplakia lesions) express much more FAS than uninfected cells. Two specific FAS inhibitors, cerulenin and C75, prevent R activation of IE (Z) and early (BMRF1) lytic EBV proteins in Jijoye cells. In addition, cerulenin and C75 dramatically attenuate IE and early lytic gene expression after B-cell receptor engagement in Akata cells and constitutive lytic viral gene expression in EBV-positive AGS cells. However, FAS inhibitors do not reduce lytic viral gene expression induced by a vector in which the Z gene product is driven by a strong heterologous promoter. In addition, FAS inhibitors do not reduce R activation of a naked DNA reporter gene construct driven by the Z promoter (Zp). These results suggest that cellular FAS activity is important for induction of Z transcription from the intact latent EBV genome, perhaps reflecting the involvement of lipid-derived signaling pathways or palmitoylated proteins. Furthermore, using FAS inhibitors may be a completely novel approach for blocking the lytic form of EBV replication.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15047835      PMCID: PMC374282          DOI: 10.1128/jvi.78.8.4197-4206.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  67 in total

Review 1.  Sterol regulatory element-binding proteins: transcriptional activators of lipid synthesis.

Authors:  J D Horton
Journal:  Biochem Soc Trans       Date:  2002-11       Impact factor: 5.407

Review 2.  Fatty acid synthase, a proficient multifunctional enzyme.

Authors:  S J Wakil
Journal:  Biochemistry       Date:  1989-05-30       Impact factor: 3.162

Review 3.  Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology.

Authors:  F P Kuhajda
Journal:  Nutrition       Date:  2000-03       Impact factor: 4.008

4.  Responsiveness of the Epstein-Barr virus NotI repeat promoter to the Z transactivator is mediated in a cell-type-specific manner by two independent signal regions.

Authors:  P M Lieberman; J M Hardwick; S D Hayward
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

5.  The Epstein-Barr virus BMLF1 promoter contains an enhancer element that is responsive to the BZLF1 and BRLF1 transactivators.

Authors:  S Kenney; E Holley-Guthrie; E C Mar; M Smith
Journal:  J Virol       Date:  1989-09       Impact factor: 5.103

6.  Epstein-Barr virus immediate-early proteins BZLF1 and BRLF1 activate the ATF2 transcription factor by increasing the levels of phosphorylated p38 and c-Jun N-terminal kinases.

Authors:  A L Adamson; D Darr; E Holley-Guthrie; R A Johnson; A Mauser; J Swenson; S Kenney
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

7.  Ceramide generation is sufficient to account for the inhibition of the insulin-stimulated PKB pathway in C2C12 skeletal muscle cells pretreated with palmitate.

Authors:  C Schmitz-Peiffer; D L Craig; T J Biden
Journal:  J Biol Chem       Date:  1999-08-20       Impact factor: 5.157

8.  Genetic and epigenetic changes in human epithelial cells immortalized by telomerase.

Authors:  D G Farwell; K A Shera; J I Koop; G A Bonnet; C P Matthews; G W Reuther; M D Coltrera; J K McDougall; A J Klingelhutz
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

9.  The Epstein-Barr virus BZLF1 protein interacts physically and functionally with the histone acetylase CREB-binding protein.

Authors:  A L Adamson; S Kenney
Journal:  J Virol       Date:  1999-08       Impact factor: 5.103

10.  Synthesis and antitumor activity of an inhibitor of fatty acid synthase.

Authors:  F P Kuhajda; E S Pizer; J N Li; N S Mani; G L Frehywot; C A Townsend
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-28       Impact factor: 11.205

View more
  38 in total

Review 1.  Lipids at the interface of virus-host interactions.

Authors:  Vineela Chukkapalli; Nicholas S Heaton; Glenn Randall
Journal:  Curr Opin Microbiol       Date:  2012-06-09       Impact factor: 7.934

Review 2.  Reprogramming of cellular metabolic pathways by human oncogenic viruses.

Authors:  John G Purdy; Micah A Luftig
Journal:  Curr Opin Virol       Date:  2019-11-22       Impact factor: 7.090

3.  Multivalent sequence recognition by Epstein-Barr virus Zta requires cysteine 171 and an extension of the canonical B-ZIP domain.

Authors:  Pu Wang; Latasha Day; Paul M Lieberman
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

4.  Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol).

Authors:  Hratch Arbach; Viktor Viglasky; Florence Lefeu; Jean-Marc Guinebretière; Vanessa Ramirez; Nadège Bride; Nadia Boualaga; Thomas Bauchet; Jean-Philippe Peyrat; Marie-Christine Mathieu; Samia Mourah; Marie-Pierre Podgorniak; Jean-Marie Seignerin; Kenzo Takada; Irène Joab
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

Review 5.  Theodore E. Woodward Award: development of novel, EBV-targeted therapies for EBV-positive tumors.

Authors:  Shannon Kenney
Journal:  Trans Am Clin Climatol Assoc       Date:  2006

6.  Epstein-Barr virus transcription activator R upregulates BARF1 expression by direct binding to its promoter, independent of methylation.

Authors:  E K Hoebe; C Wille; E S Hopmans; A R Robinson; J M Middeldorp; S C Kenney; A E Greijer
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

Review 7.  Viral activation of cellular metabolism.

Authors:  Erica L Sanchez; Michael Lagunoff
Journal:  Virology       Date:  2015-03-23       Impact factor: 3.616

8.  Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta.

Authors:  Gretchen L Bentz; Renshui Liu; Angela M Hahn; Julia Shackelford; Joseph S Pagano
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

Review 9.  Role of metabolism during viral infections, and crosstalk with the innate immune system.

Authors:  Juan José González Plaza; Nataša Hulak; Galina Kausova; Zhaxybay Zhumadilov; Ainur Akilzhanova
Journal:  Intractable Rare Dis Res       Date:  2016-05

10.  Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model.

Authors:  Gregory K Hong; Margaret L Gulley; Wen-Hai Feng; Henri-Jacques Delecluse; Elizabeth Holley-Guthrie; Shannon C Kenney
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.